Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...
The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...
Floquet control uses time-periodic drives to engineer quantum systems, creating dynamic changes in material properties ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback